Power Law company profile

CRISPR Therapeutics

Biotech & Life Sciences · Basel, Switzerland · Founded 2013 · IPO 2016 Unicorn

Gene-based medicines for patients with serious diseases

Valuation

$3.28B

Market cap · May/2026

Revenue

$100M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

15 investors on CRISPR Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

Versant Ventures

Series B+ 14 investors entered at this stage

Clough Capital Partners

Vertex Pharmaceuticals

Vivo Capital

NEA

Bristol-Myers Squibb

Abingworth

New Leaf Venture Partners

Bayer Global Investments

Celgene

Vertex Holdings

SR One

Wellington Management

GSK

Franklin Templeton Investments

CRISPR Therapeutics mafia

Startups founded by CRISPR Therapeutics alumni

Former CRISPR Therapeutics employees who went on to start their own companies. Sorted by Dealroom signal score.

Sana BiotechnologyEst. 2018

Chad CowanUnited States

Signal score69

Vernal BiosciencesEst. 2021

Christian CobaughUnited States

Signal score60

Zag BioEst. 2022

JKJohn KulmanUnited States

Signal score57

AirNexis TherapeuticsEst. 2025

Maria FardisUnited States

Signal score55

Book a demo to explore the full alumni network →

Global footprint

Where CRISPR Therapeutics has talent and traffic

AI talent share

0.6% of workforce is AI talent
(2 of 358 staff)

Core AI00%

Other AI20.56%

Non-AI workforce35699.44%

Workforce by country

6 countries with
team presence

🇺🇸 United States97.6%

🇨🇦 Canada1.1%

🇬🇧 United Kingdom0.3%

🇮🇳 India0.3%

🇧🇪 Belgium0.3%

Top 5 of 6 shown

Web traffic by country

140K monthly visits
across markets

🇺🇸 United States30.8%

🇪🇸 Spain18.6%

🇨🇦 Canada5.9%

🇵🇹 Portugal4.1%

🇦🇺 Australia3.9%

Top 5 markets shown

Patent intelligence

$107M patent portfolio · 115 active families

Estimated portfolio value

$107M

3.2% of market cap · 19× smaller than top peer Ablynx ($2B)

115 active patent families

Where CRISPR Therapeutics innovates Molecular biologyCellEx vivoCell biologyBioinformatics

Where CRISPR Therapeutics concentrates vs peers

Each axis is a top-10 topic across CRISPR Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about CRISPR Therapeutics

An AI-synthesized read of the highest-engagement posts about CRISPR Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See CRISPR Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles